PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Analisantis as agentia file reference	T				
Applicant's or agent's file reference PXWO00365/2004	FOR FURTHER ACTION See Form PCT/IPEA/416				
International application No. PCT/ES2004/000346	International filing date 23.07.2004	(day/month/year)	Priority date (day/month/year) 28.07.2003		
International Patent Classification (IPC) or national classification and IPC C07C233/83					
Applicant LABORATORIOS FARMACEUTICOS ROVI, S.A. et al.					
This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.					
2. This REPORT consists of a total of	This REPORT consists of a total of 4 sheets, including this cover sheet.				
3. This report is also accompanied b	This report is also accompanied by ANNEXES, comprising:				
a. 🛛 sent to the applicant and to					
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).					
□ sheets which supersed beyond the disclosure Supplemental Box.	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.				
b. (sent to the International B sequence listing and/or tab Box Relating to Sequence	oles related thereto, in o	computer readable form of	of electronic carrier(s)) , containing a only, as indicated in the Supplemental nstructions).		
4. This report contains indications re	lating to the following i	tems:			
Box No. I Basis of the opin	nion				
☐ Box No. II Priority					
Box No. III Non-establishm	ent of opinion with rega	ard to novelty, inventive s	tep and industrial applicability		
☐ Box No. IV Lack of unity of	invention				
⊠ Box No. V Reasoned state applicability; cita	ment under Article 35() ations and explanations	with regard to novelty, s supporting such statem	inventive step or industrial ent		
☐ Box No. VI Certain docume					
☐ Box No. VII Certain defects	in the international app	lication			
☐ Box No. VIII Certain observa	tions on the internation	al application			
Date of submission of the demand		Date of completion of this	report		
23.07.2004		06.12.2005			
Name and mailing address of the international preliminary examining authority:		Authorized Officer	aches Parage		
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d		Bertrand, F	A STATE OF THE STA		
Fax: +49 89 2399 - 4465		Telephone No. +49 89 23	99-8606		

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/ES2004/000346

	Box No. I Basis of the re	port	
1.	 With regard to the language, this report is based on the international application in the language in wh filed, unless otherwise indicated under this item. 		
	which is the language c ☐ international search ☐ publication of the int	translations from the original language into the following language, of a translation furnished for the purposes of: (under Rules 12.3 and 23.1(b)) ernational application (under Rule 12.4) nary examination (under Rules 55.2 and/or 55.3)	
2.	have been furnished to the i	s* of the international application, this report is based on (replacement sheets which receiving Office in response to an invitation under Article 14 are referred to in this and are not annexed to this report):	
	Description, Pages		
	2-29	received on 02.11.2005 with letter of 28.10.2005	
	Claims, Numbers		
	1-14	received on 02.11.2005 with letter of 28.10.2005	
	Drawings, Sheets		
	1, 2	received on 02.11.2005 with letter of 28.10.2005	
	☐ a sequence listing and/o	or any related table(s) - see Supplemental Box Relating to Sequence Listing	
3.	☐ the description, page☐ the claims, Nos.☐ the drawings, sheets☐ the sequence listing	s/figs	
4.	had not been made, since the Supplemental Box (Rule 70. the description, page the claims, Nos. the drawings, sheets the sequence listing any table(s) related the supplemental transfer of the sequence the sequenc	es (sfigs (specify): to sequence listing (specify):	
	* If item 4 applies,	some or all of these sheets may be marked "superseded."	

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/ES2004/000346

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-14

No:

Claims

Inventive step (IS)

Yes: Claims

1-14

No: Claims

Industrial applicability (IA)

Yes: Claims

1-14

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

10/563994

IAP6 Rcc'd PCT/PTO 23 JAN 2006

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/ES2004/000346

Re Item I Basis of the report

The documents mentioned herein are numbered in accordance with the order they appear in the International Search Report.

The amendments filed by the Applicant with the letter dated 28.10.2005 do not introduce any subject-matter which extends beyond the application as originally filed. They are thus admissible under Art.34(2)(b) PCT.

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The present invention relates to carrier compounds facilitating the delivery of pharmacologically active substances. None of the cited documents disclose the claimed compounds and the present application fulfills the criteria of Article 33(2) PCT, because the claimed subject-matter is new with respect to the prior art as defined in Rule 64(1) to (3) PCT.

D3 represents the closest prior art. D3 discloses compounds for the same use with some structural analogy with the claimed compounds. Due to this structural similitude, the skilled artisan would have expected at least qualitative analogous properties.

D3 discloses as well ortho as meta and para diamides. However, the ortho diamides were not tested and can thus be considered as not being preferred, although D3 intrinsically teaches that these ortho diamides are suitable.

The present comparative examples 1-3 (as compared to examples 4 and following) show that the meta and para relative position of the 2 amide groups provides for a lower heparin intracolonic absorption. This was not expectable.

The present application thus fulfills the criteria of Article 33(3) PCT, because the claimed subject-matter involves an inventive step (Rule 65(1) and (2) PCT).